NeoGenomics (NEO) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
NeoGenomics Reports 51% Revenue Growth to Record $96 Million in the First Quarter
April 30, 2019 7:05 AM EDTFT. MYERS, FL / ACCESSWIRE / April 30, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter of 2019.
First Quarter 2019 Highlights:
Consolidated revenue increased 51% to $95.6 million Clinical Services revenue increased 51% to $86.2 million Pharma Services revenue increased 45% to $9.4 million Gross profit increased 73% to $47.1 millionDouglas M. VanOort, the Company's Chairman and CEO, commented, "We are certainly pleased with our very strong... More
